


# Quantitative Proteomics

Aidan Holmes and Keighley Reisenauer




# Overview

**What is proteomics?**

**What is mass spectrometry?**

**What is quantitative proteomics?**


**How do you do a quantitative proteomics assay?**



The image features the word "JEOPARDY!" in a bold, blue, 3D-style font with a metallic sheen. The text is centered horizontally and set against a background of a grid of squares. The squares are in various shades of blue and purple, with some containing bright, multi-pointed starburst or lens flare effects. The overall aesthetic is that of a classic game show title card.

**JEOPARDY!**

# Why is proteomics useful?




**How do we identify proteins?**

LIKE THIS!



**But, actually?**

# Refresh: What is mass spectrometry?




# What is important to know about mass spec?

- m/z ratio
- **Sequence coverage**

protein set	Protein Header	Mass	Coverage	Pep Count	Different Peps	Occurrence	Rank
<u>15,185</u>	mousegp:MCHR9-086280 --  SWTR_MUS:APOA1_MOUSE: (Apo-AI) (ApoA-I).	30.6	8%	2	2	1	601
<u>13,196</u>	mousegp:MCHR7-071588 --  SWTR_MUS:APOE_MOUSE: Apolipoprotein E precursor (Apo-E).	35.8	13.20%	3	3	1	479
<u>12,189</u>	mousegp:MCHR7-063783 --  SWTR_MUS:LEG4_MOUSE: Galectin-4	36.3	34.70%	28	10	4	104
<u>7</u>	mousegp:MCHR2-001149 --  SWTR_MUS:S27A4_MOUSE: Long-chain fatty acid transport protein 4 (EC 6.2.1.-) (Fatty acid transport protein 4) (FATP-4)	72.3	2.60%	2	2	1	558

# What is a m/z ratio?




# What is sequence coverage?

MWSHPQFEKISGANGAMAKLTSAPVPLTARDVAGAVEFWTDRLGFS  
RDFVEDDFAGVVRDDVTLFISAVQDQVVPDNTLAWVWVRGLDELYAE  
WSEVVSTNFRDASGPAMTEIGEQPWGR EFALRDPAGNCVHFVAEEQ  
DENLYFQGGSHHHHHHHHHHHAGVPAPASQLTKVLAGLRHTFVVA  
DATLPDCPLVYASEGFYAMTGYGPDEV LGHNCRFLQGEGTDPKEVQ  
KIRDAIKKGEACSVRLLNYRKDGTPFWNLLTVTPIKTPDGRVSKFVGV  
QVDVTSKTEGKALADNSGVPLLVKYDHRLRDNVARTIVDDVTIAVEKA  
EGVEPGQASAVAAAAPLGAKGPRGTAPKSFPRVALDLATTVERIQQN  
FCISDPTLPDCPIVFASDAFLELTGYSREEVLGRNCRFLQGAGTDRGT  
VDQIRAAIKEGSELTVRILNYTKAGKAFWNMFTLAPMRDQDGHARFFV  
GVQVDVTAQSTSPDKAPVWNKTPEEEVAKAKMGAEAAASLISSALQG  
MAAPTANPWAAISGVIMRRKPHKADDKAYQALLQLQERDGKMKLM  
HFRRVKQLGAGDVGLVDLVQLQGSELKFAMKTLDFEMQERNKVAR  
VLTESAILAAVDHPFLATLYCTIQTDTLHFVMEYCDGGELYGLLNSQ  
PKKRLKEEHVRFYASEVLTALQYLHLLGYVYRDLKPENILLHHTGHVL  
LTDLDLSYSKGSTTPRIEKIGGAGAAGGSAPKSPKKSSSKSGGSSSG  
SALQLENYLLAEPSARANSFVGTEEYLAPEVINAAGHGPAVDWWSL  
GILIFELLYGTTPFRGARRDET FENIIK SPLKFPSKPAVSEECRDIEKL  
LVKDVGARLGSRTGANEIKSHPWFKGINWALLRHQQPPYVPRRASK  
AAGGSSTGGAAFDNY


# What is quantitative proteomics?

Proteomics


Mass Spec



# What types of quantitative proteomics are there?




# What is iTRAQ?



## iTRAQ

Isobaric **T**ags for **R**elative and **A**bsolute **Q**uantification

# How does iTRAQ work?



Treatment A



Treatment B



Treatment C






Treatment D



**What is an  
example iTRAQ  
workflow?**

# Is iTRAQ a good choice?



<http://www.hindawi.com/journals/ijpro/2013/581862/>  
<https://www.broadinstitute.org/scientific-community/science/platforms/proteomics/itraq>  
<http://www.livescience.com/37009-human-body.html>  
<http://www.rrdonnelley.com/retail/solutions/>


**How could you  
use quantitative  
proteomics in  
your project?**

# Conclusions/ Summary

What is proteomics? Refresher

What is quantitative proteomics?

What is iTRAQ protein labeling?




Tumor Biol. (2015) 36:9829–9837

DOI 10.1007/s13277-015-3758-7


RESEARCH ARTICLE

# Identification of RAB2A and PRDX1 as the potential biomarkers for oral squamous cell carcinoma using mass spectrometry-based comparative proteomic approach

Kaushik Kumar Dey<sup>1</sup> · Ipsita Pal<sup>1</sup> · Rashmi Bharti<sup>1</sup> · Goutam Dey<sup>1</sup> ·  
B. N. Prashanth Kumar<sup>1</sup> · Shashi Rajput<sup>1</sup> · Aditya Parekh<sup>1</sup> · Sheetal Parida<sup>1</sup> ·  
Priyanka Halder<sup>1</sup> · Indranil Kulavi<sup>2</sup> · Mahitosh Mandal<sup>1</sup>




# What is oral squamous cell carcinoma?



Kinda  
gross

# Figure 1: What is the experimental approach?

Characteristic	No. of patients (%)
Number of samples	10
Age (years)	
Mean	64.8±6.2
Range	51-73
Gender	
Male	6 (60%)
Female	4 (40.0)
Risk Factor	
Smoking	4 (40%)
Tobacco Chewing	6(60%)
Tumor Site	
Tongue	6 (60%)
Floor of the mouth	4(40%)




# Table 2: What are the novel molecules in this cancer?

**Table 2** A partial list of novel molecules found to be highly expressed in the OSCC tissue proteome


Gene symbol	Protein	Localization	Biological function	Fold change
<i>RAB2A</i>	Ras-related protein Rab-2A isoform a	Cytoplasm, nucleus, endoplasmic reticulum	It is a small molecular weight membranous protein that is involved in vesicular fusion and organelle biogenesis further irregularity in RAB function leads to cancer. In OSCC tissue sample, it is highly overexpressed	4.6
<i>PRDX1</i>	Peroxiredoxin-1	Nucleus, cytoplasm	It is an antioxidant which has a serious role in cancer progression and plays a significant role in the growth and development of several human cancers and influences in various cellular processes including cell survival, proliferation, and apoptosis	2.2
<i>CDSN</i>	Corneodesmosin	Cytoplasm, nucleus	It is expressed in epithelial cells in the infiltrative aggressive relapsing tumor of basal cell carcinoma	2.1
<i>SCRNI</i>	Secernin-1 isoform c	Cytoplasm, nucleus	Secerinin-1 is a cytosolic protein that excites exocytosis in mast cells, but the mechanisms of its function in exocytosis remain unexplored	2.1
<i>RAB14</i>	Ras-related protein Rab-14	Cytoplasm, nucleus	It is a low molecular mass GTPases that are involved in intracellular membrane trafficking. It is shown to be overexpressed in human non-small cell lung carcinoma which has severe role in tumorigenesis	1.9
<i>LUM</i>	Lumican	Cytoplasm	Lumican belongs to the family of small interstitial has a significant role in regulating cell behavior repair, and cancerous growth. In stromal tissue growth and invasion of various types of cancer aggressiveness during tumor progression	



# Why do we care about **RAB2A** and **PRDX1**?



# Figure 2A: What is the **RAB2A** peptide MS spectra?




# Which peak corresponds to RAB2A fragment?

67 / 89

4506365	RAB2A	ras-related prc32.08	4	6	6	7	212	23.5	6.54													
										TASNVEEAF2	2	1	4506365	N-Term(f 0.949	1.059	1.080	4.40	0	2	1782.948	891.9777;0.286276;30.76845833	
										IQEGVFDIN1	2	1	4506365	N-Term(f 0.850	1.113	1.121	3.60	0	3	2049.084;683.6998;-0.30903832.55899		
										GAAGALLV.1	4	1	4506365	N-Term(f 1.860	0.797	1.064	4.16	1	3	1619.943;540.6525;4.940307;28.579895		
										GAAGALLV.1	4	1	4506365	N-Term(f 1.110	1.115	0.990	5.29	0	2	1463.834	732.4207	0.170609;34.94948333
										LQIWDTAG1	4	1	4506365	N-Term(f 1.059	1.024	0.881	4.22	0	2	1694.861;847.9342;-0.38979332.34504333		
										SCLLQFTD1	2	1	4506365	N-Term(f 14.448	0.857	1.160	3.40	1	3	1657.901;553.3052;0.302795;22.91716		
4759000	RAB3D	ras-related prc15.55	2	2	2	2	219	24.5	4.95													
										LADDLGFEI1	1	1	4759000	N-Term(f 0.780	0.762	0.822	3.34	0	3	1947.996;650.0035;-0.908403151.92689333		
										YADDSFTP.1	2	1	4759000	N-Term(f 0.993	1.083	0.902	5.15	0	2	2368.206;1184.606;4.819371;52.248455		
19923260	RAB4A	ras-related prc11.93	1	2	2	2	218	24.4	6.07													
										SCLLHQFIE1	1	1	19923260	N-Term(f 0.298	1.052	1.062	3.33	0	3	1551.847;517.9539;13.39495;27.39915333		
										FKDDSNHT1	1	1	19923260	N-Term(f 1.062	0.940	1.524	3.66	1	4	2213.150;554.0430;-2.72509216.45045		
19923262	RAB5A	ras-related prc16.28	5	2	2	2	215	23.6	8.15													
										AVDFQEAQ.1	1	1	19923262	N-Term(f 1.162	2.533	0.921	3.71	0	3	2968.430;990.1482;5.95015948.36561667		
										FEIWDTAG.1	5	1	19923262	N-Term(f 0.569	1.031	0.950	3.29	0	2	1495.728;748.3677;-1.01302927.53206833		
34403020	RAB6A	ras-related prc8.00	3	1	1	1	175	19.9	5.07													
										AKELNVMF1	3	1	34403020	N-Term(f 0.827	0.989	1.086	5.18	1	3	2013.143;671.7193;0.992231;30.28343		
34147513	RAB7A	ras-related prc33.82	1	6	6	14	207	23.5	6.70													
										DPENFFPVV3	1	1	34147513	N-Term(f 0.914	0.967	0.916	4.33	0	2	1763.958	882.4827;0.606693;41.31111667	
										NNIPYFETS.2	1	1	34147513	N-Term(f 3.162	0.825	1.038	3.73	0	2	1571.830;786.4186;-0.51128022.332435		

# Figure 2B: What is the **PRDX1** peptide MS spectra?





# Which peak corresponds to PRDX1 fragment?

4505591 PRDX1	peroxiredoxin48.74	1	10	13	34	199	22.1	8.13											
<b>TIAQDYGV12</b>	<b>1</b>	<b>1</b>	<b>4505591</b>	<b>N-Term(r 0.852</b>	<b>1.030</b>	<b>0.920</b>	<b>4.76</b>	<b>0</b>	<b>2</b>	<b>1395.808;698.4078;-0.15768025;64602</b>									
LVQAFQFTL2	1	1	4505591	N-Term(r 0.538	0.997	0.971	4.62	0	2	1484.836;742.9220;1.119510133.41626									
ATAVMPDG2	1	1	4505591	N-Term(r 0.563	0.961	0.957	4.08	0	2	1452.779;726.8932;2.240604;18.19584333									
GLFIIDDK	2	2	5453549;	N-Term(iTRAQ4plex); K8(iTRAQ4plex)	3.81	0	2	1208.711;604.8596	-0.80717229.72694										
DISLSDYK	2	1	4505591	N-Term(r 0.514	0.949	0.981	3.64	0	2	1228.663;614.8355	-2.02768322.51929								
ATAVMPDG1	1	1	4505591	N-Term(r 0.497	0.915	0.993	3.08	0	2	1452.779.726.8932;2.240604;18.19584333									
ADEGISFR	1	1	4505591	N-Term(r 0.995	0.906	1.117	3.02	0	2	1038.535;519.7714;1.933327117.43708167									
GLFIIDDKG15	2	2	5453549;	N-Term(iTRAQ4plex); K8(iTRAQ4plex)	4.79	1	2	1148.014;824.5111	116.840275130.97155333										
TIAQDYGV15	1	1	4505591	N-Term(r 6.179	0.774	1.085	5.71	1	3	2271.235;757.75	5.745529;31.21478833								
QGGLGPMN3	1	1	4505591	N-Term(r 1.392	1.043	0.958	6.60	1	2	2067.174	1034.090;5.670816	24.23098333							
ATAVMPDG1	1	1	4505591	N-Term(r 2.046	0.812	0.985	5.37	1	2	2534.333;1267.670;6.395524;24.24746333									
QITVNDLPV5	2	2	32189392	N-Term(iTRAQ4plex)			4.22	0	2	1355.784;678.3960;6.235014;23.08444333									
KQGGLGPM2	1	1	4505591	N-Term(r 1.334	1.099	0.837	4.98	1	2	2183.256;1092.131	-0.76532630.25304333								
IGHPAPNFK1	1	1	4505591	N-Term(r 1.062	1.314	1.046	3.35	0	3	1268.732;423.5822	-2.60692013.20725667								

TIAQDYGVI

MH	m/z	deltaM(pf RT)
1395.808	698.4078	-0.15768025.64602

# Figure 3: How were the iTRAQ results validated?




# Western Blots




# Figure 4 A-B: Where do **RAB2A** and **PRDX1** localize?


(A) RAB2A

Normal



**Figure 4C: How did they compare protein expression?**






# QUIZ TIME


What are the 3 gene ontologies?  
Bonus: give an example!

# Figure 2D: How did they sort their proteins based on cellular localization?



**(D)** Cellular Localization

## Figure 2C: How did they sort their proteins based on biological processes?




(C) Biological Process

# What are the main takeaways from the paper?

Proteomics methods are important

Gene ontologies

Quantitative proteomics are helpful for determining biomarkers



# How are biomarkers useful in cancer research?

How does gene ontology help us move forward with quantitative proteomic data?


Why is biomarker discovery a helpful tool in cancer diagnosis?

Future research

Confirm biomarkers in vivo

Determine specificity and sensitivity

Improve biomarker strategies



QUESTIONS

